BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200511
DTEND;VALUE=DATE:20200513
DTSTAMP:20260515T084334
CREATED:20180202T092329Z
LAST-MODIFIED:20200319T094546Z
UID:9152-1589155200-1589327999@www.pharmajournalist.com
SUMMARY:SMi’s 20th Annual Pain Therapeutics Conference
DESCRIPTION:SMi’s 20th Annual Pain Therapeutics Conference\nDiscover Cutting Edge Research and Novel Therapeutics in the Pipeline \nConference: 11 and 12 May 2020\nLocation: REMOTE ACCESS ONLY\nWebsite: http://www.pain-therapeutics.co.uk/PharmaJournWL \nAnnouncement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.pain-therapeutics.co.uk \nThe price to be a part of this conference is £999 (remote access) and registration is available via the conference website at www.pain-therapeutics.co.uk \nThe 20th Annual Conference will overview the current state of pain treatment starting with research essentials including choosing the right preclinical models to overviewing clinical success up to date\, highlighting cutting-edge research and evaluating the potential of drug candidates in the pipelines of leading pharmaceuticals. \n \nThis year we are introducing the Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Within this theme talks will address the latest biomarker discoveries\, bridging the translational gap\, differences of pain pathology across sexes and consequently\, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment.  \nPresentations on clinical stage research will highlight current struggles of opioid-based treatments and discuss results of treatments with non-opioid targets; such as the recently researched cannabinoid receptor 2\, nociception/orphanin FQ peptide (NOP) receptor\, ENKephalinase and NGF receptors. Furthermore\, neuro-immune interactions and their role in pain pathology will be discussed as an anticipated approach for providing more effective therapy for chronic pain. Additionally\, the therapeutic efficacy of neurotoxins will be addressed exploring novel botulinum-based constructs.  \nJoin SMi’s leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires. \nEvent Hashtag: #SMiPain \nView the full agenda: http://www.pain-therapeutics.co.uk/PharmaJournWL \nWHO SHOULD ATTEND \nChief Executive Officer\, Chief Scientific Officers\, Chief Medical Officers\, Managing Directors\, CEO\, Head of Department\, Principal Research Scientists\, Clinical lead\, Clinical Operations in the following fields: \n\nPain and Migraine\nInflammation\nChronic Pain\nNeuropathic Pain\nAnalgesic pre-clinical development\nAnaesthesia and Pain Management\nCNS clinical trials\nIon Channel Pharmacology\nPharmacology Intelligence\nTranslational science\nDrug development\nExploratory development\n\nEARLY BIRD-RATES \n\nBOOK BY 28TH FEBRUARY AND SAVE £200\nBOOK BY 31ST MARCH AND SAVE £100
URL:https://www.pharmajournalist.com/event/smi-pain-therapeutics-conference/
LOCATION:REMOTE ACCESS ONLY
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200511
DTEND;VALUE=DATE:20200513
DTSTAMP:20260515T084334
CREATED:20180307T074833Z
LAST-MODIFIED:20200323T125717Z
UID:11545-1589155200-1589327999@www.pharmajournalist.com
SUMMARY:Highly Potent Active Pharmaceutical Ingredients (HPAPI)
DESCRIPTION:SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th – 12th May 2020. \nAnnouncement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.highlypotentapi.com \nThe price to be a part of this conference is £999 (remote access) and registration is available via the conference website www.highlypotentapi.com \n \nHPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology\, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits\, assessing hazards\, implementing risk procures\, translating risk assessment into facility engineering\, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines. \nAttend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry. \nNetwork and learn from leading professionals such as: \nCHAIR FOR 2020 – Justin Mason-Home\, Director\, HPAPI Project Services Limited \nKEY SPEAKERS INCLUDE: \nPascal Michoux\, Vice President\, Global EHS Teva api & Biologics\, teva API Italy\nWilliam Hawkins\, Manager Occupation Toxicology\, GsK\nBrian Edwards\, Chair\, Pharmaceutical Human Factors Group\, CIeHf\nThomas Adam\, Head of GQA Chemical APIs\, Bayer AG\nIldikó Ziegler\, QA Manager\, Gedeon Richter\nFrancois D’Hooge\, ADC Project Manager\, Gamamabs Pharma\nAndreas Schreiner\, Head of Validation\, Novartis \nFEATURED HIGHLIGHTS: \n\nExplore HPAPI manufacturing with 8 big pharma from both the toxic substance and the employees’ perspective\nGain better understanding of human factors and ergonomics aspects and their role in improving production performance with the Chartered Institute of Ergonomics and Human Factors\nDeep dive into the oncology market and ADC production\, the main driver of the HPAPI industry\nLearn what it takes to create a safety company culture and how to better train your employees on risk perception\n\nView the full agenda: www.highlypotentapi.com \nContact Info: \nT: +44 (0) 20 7827 6164\nE: nhoward@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/highly-potent-active-pharmaceutical-ingredients-hpapi/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd.":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
END:VCALENDAR